Inotiv reported a 6.7% increase in revenue for the fourth quarter of fiscal year 2020, primarily driven by the PCRS acquisition. However, the company experienced a net loss due to increased costs associated with capacity expansion, infrastructure development, and general administrative expenses.
Revenue increased by 6.7% compared to the fourth quarter of fiscal 2019, reaching $15.774 million.
Service revenue increased by 11.1%, driven by nonclinical services revenues and the PCRS acquisition.
Net loss amounted to $1.792 million, or $0.16 per diluted share, compared to net income of $290,000, or $0.03 per diluted share in Q4 2019.
The company's book-to-bill ratio for the quarter was 1.48x, and the backlog at the end of the quarter was $43.8 million.
Inotiv anticipates continued internal growth by adding services and expanding capacity, along with exploring selective external growth opportunities to broaden its platform and drive shareholder value. The company intends to enhance client experience, build a winning culture, and create a gratifying work environment, while also updating governance practices and proposing a formal corporate name change to Inotiv, Inc.